Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT07197671
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 90Y-NM600 — DRUG
    NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity

Study Details

Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.

Key Dates

Start date
Jul 1, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1A: Dose Level -1
    20 mCi x 1 90Y-NM600
  • Experimental: Phase 1A: Dose Level 1
    35 mCi x 1 90Y-NM600
  • Experimental: Phase 1A: Dose Level 2
    70 mCi x 1 90Y-NM600
  • Experimental: Phase 1A: Dose Level 3
    105 mCi x 1 90Y-NM600
  • Experimental: Phase 1A: Dose Level 4
    140 mCi x 1 90Y-NM600
  • Experimental: Phase 1B: Single Dose
    Informed by Phase 1A
  • Experimental: Phase 1B: Multi-dose
    Informed by Phase 1A and Single Dose Phase 1B

Primary Outcome Measure

Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600 [ Time Frame: baseline screening, Day 7 after 86Y-NM600 injection ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UW Carbone Cancer CenterMadisonWisconsin53792-

Find similar trials in Madison, WI

By research site
UW Carbone Cancer Center· Madison, WI

Related Studies